Utilization of Biosimilars: Achieving Value-Based Plan Management Through Access, Outcomes, and Communication

Utilization of Biosimilars: Achieving Value-Based Plan Management Through Access, Outcomes, and Communication

On-Demand Webcast

This webcast is based on live proceedings from the 2018 Health Care Quality Congress.

Provided by North American Center for Continuing Medical Education, LLC, an HMP Company, and the National Committee for Quality Assurance

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save

Faculty

Jonathan Kay, MD
Professor of Medicine and Timothy S. and
Elaine L. Peterson Chair in Rheumatology
University of Massachusetts Medical School
Physician, UMass Memorial Medical Center 
Worcester, Massachusetts

Intended Learners

This activity is designed for the seasoned health care management professional responsible for managing, implementing and assessing the Health Plan Accreditation survey process and those professionals gathering, analyzing, or reporting HEDIS data.

Learning Objectives

After completion of this activity, participants should be able to:

  • Highlight the clinical, cost, regulatory, and stakeholder considerations that impact the adoption of biosimilar treatments in the United States
  • Review the key clinical and regulatory concepts surrounding biosimilars including totality of evidence, complex data analytics, indication extrapolation, and interchangeability/substitution
  • Evaluate the current evidence surrounding biosimilar safety and efficacy, economic, post-approval data, and resources available to improve provider/patient confidence
  • Describe how biosimilars complement the evolving landscape of value-based, quality health care
  • Initiate strategies to address barriers to biosimilar adoption through formulary, plan, and value-based reimbursement as well as patient/provider communication strategies
Activity Overview

This on-demand webcast is available with synchronized slides and audio.

To be eligible for documentation of credit, participants must complete the educational activity, complete the 10-question post-test with a score of 60% or better, and complete the evaluation form.

After successful completion of the post-test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring webcast.

Release Date: December 28, 2018
Expiration Date: December 28, 2019
Estimated time to complete: 60 minutes

There is no fee associated with this activity.

For questions regarding this educational activity, please call 609-371-1137.

Hardware/Software Requirements

All educational activities are accessible via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. Windows Media Player or compatible alternative, sound card, and speakers are required for streamed audio. The latest version of the Adobe Flash Player is suggested for video programs. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

Accreditation

In support of improving patient care, the National Committee for Quality Assurance (NCQA) is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE) and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for the healthcare team.

CME

NCQA designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE

This educational activity is approved for 1 nursing education contact hour.

CPE

This activity is approved for 1 contact hour (.01 CEU) of continuing pharmacy education (UAN JA0004597-0000-18-020-H04-P).

This educational activity is a knowledge-based activity.

Clinical Reviewer: Victor Caraballo, MD, Senior Medical Director, Quality Management, Independence Blue Cross, Philadelphia, PA

Nurse Reviewer: Johann Chanin, Senior Consultant, Steadman Group, Denver, CO

Planning Committee

The planning committee comprises Victor Caraballo, MD; Johann Chanin, MSN, RN, PCMH CCE; Jonathan Kay, MD; Vashon Coehins, Jennifer D'Alessandro, and Bart Ecker, NCQA; and Kristin Ciszeski, Mary Johnson, Michael Kearney, Randy Robbin, and Susan Yarbrough, NACCME.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. Kay: Research Grants (paid to the University of Massachusetts Medical School)—Gilead Sciences Inc., Pfizer Inc., UCB, Inc.; Consultant— Amgen Inc., Boehringer Ingelheim GmbH, Celgene Corp., Celltrion Healthcare Co. Ltd., Janssen Biotech Inc., Merck Sharp & Dohme Corp., Myriad Genetics, Inc., Pfizer Inc., Roche Laboratories, Inc., Samsung Bioepis, Sandoz Inc.

Dr. Caraballo and Ms. Chanin have disclosed no relevant financial relationships with any commercial interests.

Ms. Coehins, Ms. D'Alessandro, Mr. Ecker, Ms. Ciszeski, Ms. Johnson, Mr. Kearney, Mr. Robbin, and Ms. Yarbrough have disclosed no relevant financial relationships with any commercial interests.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

The faculty have disclosed no off label/unapproved uses of drugs and/or devices will be discussed in the presentations.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2018 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Grant Support

Supported by an educational grant from Sandoz Inc.